October 1, 2018

Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California.

The Cell & Gene Meeting on the Mesa is organized by the Alliance of Regenerative Medicine and the Stanford Stem Cell Clinical Center at UC San Diego. A live video webcast will be available at http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.

Media Contact:
Solid Biosciences
Kate Niazi-Sai
617-337-4680
media@solidbio.com

Investor Contact:
Kendall Investor Relations
Carlo Tanzi, Ph.D.
617-337-4680
investors@solidbio.com

SolidBioLogoDigitalRGB.png

Source: Solid Biosciences Inc.

Related news

Sep13

Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors.

Aug10

- IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed -

Jun26

Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities

Jun18

- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET

May19

- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

May15

Solid Biosciences today announced that new preclinical data from its DMD programs will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT).

May10
Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial
Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Pages

More information about Solid?

Please subscribe to receive our latest news